913686-05-2

Upstream product

• 5586-73-2 3-diphenylpropyl amine 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 348611-52-9 N-(2-morpholin-4-yl-ethyl)-3,3-diphenyl-propionamide 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 4279-81-6 3,3-diphenylpropanal 
• 119-61-9 benzophenone 
• 17792-17-5 ethyl 3,3-diphenylacrylate 
• 7476-18-8 3,3-diphenyl-propionic acid ethyl ester 
• 606-83-7 3,3-Diphenylpropionic acid 
• 20017-67-8 3,3-diphenylpropan-1-ol 
• 89583-07-3 N-(2-bromoethyl)morpholine 

Downstream Products

• 938467-15-3 3-[3-(3,3-diphenylpropyl)-3-(2-morpholin-4-ylethyl)ureido]benzoic acid methyl ester 
• 938467-58-4 3-[3-(3,3-diphenylpropyl)-3-(2-morpholin-4-ylethyl)ureido]benzoic acid 
• 938764-55-7 C₂₉H₃₃N₇O₂ 

Relevant academic research and scientific papers

Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism

A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essential to finding a compound suitable for oral dosing. Calcimimetic 18 exhibited excellent in vivo potency in a 5/6 nephrectomized rat model and cross-species pharmacokinetics.

New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas

Starting from Fendiline and R-568, we identified a novel series of urea compounds as positive allosteric modulators of the calcium sensing receptor (CaSR), as part of a program to identify novel therapeutics for secondary hyperparathyroidism. Initially id

UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS

The present invention provides compounds of formula (I): in which Y is oxygen or sulphur; R1 and R”1 are optionally substituted aryl, heteroaryl or a fused ring structure, R2and R'2 are each H, or optionally substituted alkyl, alkylaminoalkyl or dialkylaminoalkyl, or R2 and R'2 and their N form a saturated or unsaturated optionally substituted heterocycle, R3 represents a group of formula -(CH2)P-Ar-Rn, wherein p is 0 or 1 and, when p is 1, is optionally substituted, Ar is aryl or heteroaryl, and each R is H, halogen; hydroxyl; trifiuoromethyl; linear and branched alkyl, alkenyl, alkynyl, and alkoxyl groups, all optionally further substituted by one or more of hydroxy groups, halogen atoms, alkoxy groups, amino groups, and alkylthio groups; linear and branched alkoxyl groups; linear and branched thioalkyl groups; aryl groups; aralkyl groups; aralkoxy groups; aryloxy groups; perfluoroalkyl; -CN; -NR4R5, -C(=X)NR4R5,-O-C(=X)NR4R5, -SO2NR4R5, - Alk-NR4R5, -NZC(=X)(NH)qR6, -Alk-NZC(=X)(NH)qR6, -C(=X)R6, -Alk-C(=X)(NH)qR6, -NHSO2R7, -SO2R7, -SOR7, -SR7, or is a saturated or unsaturated heterocyclyl group, and salts and esters thereof, are useful in the treatment of conditions susceptible to modulating ion channels, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.

UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF

The present invention provides compounds of formula (I): in which R 1, R'1, R2, R'2, R3, Y and G have the meanings given in the description, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.